Latest news with #Lonza
Yahoo
2 days ago
- Business
- Yahoo
Cell and Gene Therapy Supply Chain Software Market Report 2025-2035: 170+ Software Solutions Providers Fueling Fragmented Cell & Gene Therapy Supply Chain Market Growth
The global cell and gene therapy supply chain software market is set to expand from USD 0.27 billion in 2025 to USD 1.32 billion by 2035, at a CAGR of 15.2%. Driven by demand for advanced therapies, the market is enhanced by cloud-based technologies and key players like Azenta Life Sciences and Lonza. Cell and Gene Therapy Supply Chain Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Supply Chain Software Market: Industry Trends and Global Forecasts to 2035: Distribution by Process Component, Type of Software, Mode of Deployment, Scale of Operation, Type of End-user and Key Geographical Regions" report has been added to offering. The global cell and gene therapy supply chain software market is estimated to grow from USD 0.27 billion in 2025, to USD 1.32 billion by 2035, at a CAGR of 15.2% during the forecast period, to 2035. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: GROWTH AND TRENDS Advanced therapies are gradually evolving the face of modern healthcare. These new regenerative and immunotherapy modalities have the potential to improve treatment outcomes by providing viable therapy solutions to patients who currently have limited or no treatment options. Given the nature of these treatment modalities, these therapies have a limited lifespan, even when shipped under temperature-controlled conditions. It becomes increasingly important to track the source of the sample from the time of its collection, current location and manufacturing processes. Following this fact, for the commercial success of such therapies, an effective manufacturing platform and a robust supply chain model are imperative. It is worth mentioning that a sustainable supply chain enables further reductions in the cost of goods and, in turn, prices of such therapies. The supply chain for innovative therapies is complicated from the outset and given the interdependencies amongst multiple stakeholders, it becomes challenging to manage and streamline the overall process. This has reinforced the need for bespoke and integrated software solutions to help innovators manage the critical intricacies of the supply chain. These software systems have huge potential to manage a multitude of events, maintain the chain of identity and custody, and enable stakeholders to optimize the complex supply chains, while also ensuring compliance with global regulatory standards. Driven by the growing demand for cell and gene therapies and the availability of easy to integrate software solutions to manage cell and gene therapy supply chain, this market is expected to grow significantly in the foreseen future. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: KEY INSIGHTS The report delves into the current state of the cell and gene therapy supply chain software market and identifies potential growth opportunities within the industry. Some key findings from the report include: Presently, close to 175 cell and gene therapy supply chain software solutions are available in the market; of these, 22% are laboratory information management systems. Over 20% of the cell and gene therapy supply chain software solutions can be deployed both on-premises and over the cloud, offering flexibility as well as contact-less options for the end-users. The current market landscape of cell and gene therapy supply chain software providers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US. The growing interest in this domain is evident from the rise in partnership activity; in fact, 40 partnership deals related to cell and gene therapy supply chain software were inked in 2023. Several investors, having realized the opportunities associated within supply chain management software domain, have invested USD 3 billion across various funding rounds in the past 10 years. Driven by the increasing pace of innovation and partnership activity, the market for cell and gene therapy supply chain software is poised to witness steady growth in the foreseeable future. The cell and gene therapy supply chain software market is anticipated to grow at a CAGR of 15.2%, till 2035; North America is expected to capture the majority share (over 45%) of the market by 2035. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: RESEARCH COVERAGE Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cell and gene therapy supply chain software market, focusing on key market segments, including process component, type of software, mode of deployment, scale of operation and key geographical regions. Market Landscape: A comprehensive evaluation of cell and gene therapy supply chain software solutions, considering various parameters, such as type of software, key features, application area, mode of deployment, scale of operation, regulatory guidelines followed and type of end-user. Additionally, it includes a detailed list of developers providing cell and gene therapy supply chain software solutions, along with analysis based on various parameters, such as year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe, Asia-Pacific, and rest of the world) and most active players based on the number of software solutions offered. Company Competitiveness Analysis: A comprehensive competitive analysis of cell and gene therapy supply chain software solution providers, examining factors, such as developer strength and product portfolio strength. Company Profiles: In-depth profiles of key cell and gene therapy supply chain software solution providers, focusing on company overviews, software solutions portfolio, financial information, recent developments and an informed future outlook. Funding and Investment Analysis: A detailed evaluation of the investments made in this domain, encompassing seed funding, venture capital, debt financing, grants / awards, capital raised from IPOs and subsequent offerings. Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2019, covering acquisitions, platform utilization agreements, service alliances, platform integration agreements, product development agreements, service agreements and other agreements. Platform Utilization Agreements in Supply Chain Software Solutions Market: An in-depth analysis of the platform utilization agreements inked in this domain since 2019, providing information on the different types of software utilized by end-users in the cell and gene therapy supply chain. Stakeholder Need Analysis: A qualitative evaluation of the current and future needs of various stakeholders in the cell and gene therapy supply chain, including patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators. This section provides a summary of the distinct needs of these stakeholders and presents our opinion (drawn from historical and current trends) on the impact of these needs on the supply chain and how the industry is preparing to cater to these needs. Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth. Sample Players in the Cell and Gene Therapy Supply Chain Software Market, Profiled in the Report Include: Azenta Life Sciences Biocair BioLife Solutions CareDx Cryoport Lonza NMDP BioTherapies TraceLink TrakCel Veeva Systems Emerson LabVantage Solutions Marken MasterControl QuickSTAT Siemens Stafa Cellular Therapy Steiner STEMSOFT Software TECHNIDATA Thermo Fisher Scientific KEY QUESTIONS ANSWERED IN THIS REPORT How many companies are currently engaged in this market? Which are the leading companies in this market? What kind of partnership models are commonly adopted by industry stakeholders? What are the factors that are likely to influence the evolution of this market? What is the current and future market size? What is the CAGR of this market? How is the current and future market opportunity likely to be distributed across key market segments? REASONS TO BUY THIS REPORT The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants. Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies. The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects. ADDITIONAL BENEFITS Complimentary PPT Insights Packs Complimentary Excel Data Packs for all Analytical Modules in the Report 10% Free Content Customization Detailed Report Walkthrough Session with Research Team For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell and Gene Therapy Supply Chain CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Saba Yemen
7 days ago
- Automotive
- Saba Yemen
European Stocks Rise Amid Optimism Over Trade Deal with the U.S.
Brussels – SABA: European stocks climbed on Wednesday, led by gains in the automotive sector, as optimism grew over a potential trade agreement with the United States following Washington's recent deal with Japan. The Stoxx 600 index rose nearly 1% to 549.6 points, recovering from three consecutive sessions of losses. Meanwhile, the UK's FTSE 100 extended its winning streak to a fifth straight session, hitting a record high. Other regional indices also advanced, with France's CAC 40 leading the gains, jumping 1.3%. The auto manufacturing sector was the top performer, surging 3.4%, tracking gains in Asian competitor stocks. Shares of Porsche soared 7.6%, while Mercedes-Benz climbed 5.8%. Swiss company Lonza was among the strongest performers, rising 5.4% after surpassing profit expectations, driven by its pharmaceutical manufacturing unit. However, shares of ASM International fell 7.7%, weighing on the tech sector and marking the biggest decline on the Stoxx 600. German software giant SAP also dropped 3.5% after reporting higher Q2 profits due to cost-cutting and increased demand but refraining from raising its full-year earnings forecast. The market rally reflects growing confidence in easing trade tensions, with investors closely watching for further developments in U.S.-Europe trade negotiations. Whatsapp Telegram Email Print more of (Economy)
Reuters
23-07-2025
- Business
- Reuters
Lonza tops core profit forecast driven by main drug manufacturing business
July 23 (Reuters) - Switzerland's Lonza (LONN.S), opens new tab posted 23% growth in its half-year core profit on Wednesday, beating market expectations, driven by a strong performance in its contract drug manufacturing (CDMO) business and contributions from its Vacaville site in the U.S. Lonza, which produces monoclonal antibodies used in a new class of Alzheimer's drugs, reported core earnings before interest, taxes, depreciation and amortization (EBITDA) of 1.1 billion Swiss francs ($1.39 billion). Analysts polled by Vara Research had forecast a core profit of 993 million francs. Lonza had said in December it wanted to exit its capsules and health ingredients (CHI) business, as a decline in demand for pharmaceutical supplies since the end of the COVID-19 pandemic has been weighing on the group's performance. The company is well on track with the internal preparations to carve out and exit the business, it said in Thursday's earnings statement. Lonza's finance chief Philippe Deecke said on a call with journalists that it was too early to estimate a value of a possible sale. According to analysts, such deal could be valued between 2 billion and 4 billion francs. Lonza reported half-year sales of 3.6 billion francs, slightly ahead of the consensus estimate of 3.5 billion francs. Sales in the CDMO business, which made up 86% of the group's sales, benefited from strong demand in mammalian, bioconjugates and small molecules technology platforms. Based on this, Basel-based Lonza raised its outlook for the CDMO business, expecting sales growth of 20-21% at constant exchange rates, versus close to 20% previously, and a core EBITDA margin of 30-31%, against a prior target of close to 30%. Lonza also expects its second-half sales to be higher than in the first half of the year, as its delivery pipeline is more weighted towards the latter part of the year. The pharmaceutical supplier said it assumes a negative currency exchange effect of 2.5% to 3.5% on its annual sales and core EBITDA, mainly due to the weakening U.S. dollar versus Swiss franc. Lonza makes roughly 66% of its sales in foreign currencies, of which the U.S. dollar represents the largest part. ($1 = 0.7936 Swiss francs) (This story has been refiled to correct a typo in the headline)
Reuters
23-07-2025
- Business
- Reuters
Lonza's tops core profit forecast driven by main drug manufacturing business
July 23 (Reuters) - Switzerland's Lonza (LONN.S), opens new tab posted 23% growth in its half-year core profit on Wednesday, beating market expectations, driven by a strong performance in its contract drug manufacturing (CDMO) business and contributions from its Vacaville site in the U.S. Lonza, which produces monoclonal antibodies used in a new class of Alzheimer's drugs, reported core earnings before interest, taxes, depreciation and amortization (EBITDA) of 1.1 billion Swiss francs ($1.39 billion). Analysts polled by Vara Research had forecast a core profit of 993 million francs. Lonza had said in December it wanted to exit its capsules and health ingredients (CHI) business, as a decline in demand for pharmaceutical supplies since the end of the COVID-19 pandemic has been weighing on the group's performance. The company is well on track with the internal preparations to carve out and exit the business, it said in Thursday's earnings statement. Lonza's finance chief Philippe Deecke said on a call with journalists that it was too early to estimate a value of a possible sale. According to analysts, such deal could be valued between 2 billion and 4 billion francs. Lonza reported half-year sales of 3.6 billion francs, slightly ahead of the consensus estimate of 3.5 billion francs. Sales in the CDMO business, which made up 86% of the group's sales, benefited from strong demand in mammalian, bioconjugates and small molecules technology platforms. Based on this, Basel-based Lonza raised its outlook for the CDMO business, expecting sales growth of 20-21% at constant exchange rates, versus close to 20% previously, and a core EBITDA margin of 30-31%, against a prior target of close to 30%. Lonza also expects its second-half sales to be higher than in the first half of the year, as its delivery pipeline is more weighted towards the latter part of the year. The pharmaceutical supplier said it assumes a negative currency exchange effect of 2.5% to 3.5% on its annual sales and core EBITDA, mainly due to the weakening U.S. dollar versus Swiss franc. Lonza makes roughly 66% of its sales in foreign currencies, of which the U.S. dollar represents the largest part. ($1 = 0.7936 Swiss francs)
Reuters
23-07-2025
- Business
- Reuters
Lonza's half-year core profit tops market expectations
July 23 (Reuters) - Swiss contract drug manufacturer Lonza (LONN.S), opens new tab reported a rise in its half-year core earnings on Wednesday, beating market expectations, aided by contributions from its Vacaville site in the U.S and strong performance in the mammalian, bioconjugates and small molecules technology platforms. Lonza reported earnings before interest, taxes, depreciation and amortization (EBITDA) of 1.1 billion Swiss francs ($1.39 billion) for the first six months of 2025, compared with 893 million francs in the same period last year. Analysts polled by Vara Research had forecast a core profit of 993 million francs. ($1 = 0.7936 Swiss francs)
